
Opinion|Videos|August 29, 2024
Review of Data from EHA 2024 of Emerging Novel Bispecific Antibodies
Key opinion leaders provide concise insights on the potential of bispecific antibodies as emerging novel therapeutic agents for relapsed/refractory chronic lymphocytic leukemia.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- Briefly share perspective/insights on emerging novel agents in R/R CLL: Bispecific antibodies
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
2
Nonresponse to Bridging Therapy and Peak ALC After Cilta-Cel Are Associated With Neurotoxicity, NRM in Myeloma
3
FDA Underscores Risks Associated With DPD Deficiency and Capecitabine/5-FU Use in Cancer Care
4
FDA Updates Axi-Cel Label to Remove Limitation of Use in R/R PCNSL
5





































